Article
Immunology
Klaus Nunes Ficher, Yasmin Dreige, Paulo Ricardo Gessolo Lins, Alexandra Nicolau Ferreira, Juliana Toniato de Rezende Freschi, Kamilla Linhares, Suelen Stopa Martins, Luciana Custodio, Marina Cristelli, Laila Viana, Daniel Wagner Santos, Renato de Marco, Maria Gerbase-DeLima, Henrique Proenca, Wilson Aguiar, Monica Nakamura, Claudia Rosso Felipe, Jose Medina Pestana, Helio Tedesco Silva Jr
Summary: This study analyzed the long-term efficacy and safety of everolimus or mycophenolate in combination with tacrolimus for kidney transplant recipients. The results showed that in de novo low/moderate immunologic risk patients, using a single dose of rabbit antithymocyte globulin followed by reduced tacrolimus concentrations and everolimus resulted in similar effectiveness and renal function compared to the standard immunosuppressive regimen.
Review
Medicine, General & Internal
Ruvistay Gutierrez-Arias, Maria Jose Martinez-Zapata, Monica C. Gaete-Mahn, Dimelza Osorio, Luis Bustos, Joel Melo Tanner, Ricardo Hidalgo, Pamela Seron
Summary: Due to the limited number of studies and heterogeneity in interventions and outcomes, the effects of exercise training in lung transplant patients are uncertain with a high risk of bias.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Review
Pharmacology & Pharmacy
Da-Hoon Lee, Hana Lee, Ha-Young Yoon, Jeong Yee, Hye-Sun Gwak
Summary: There is a correlation between the POR*28 genotype and the pharmacokinetics of TAC in early post-transplantation period in adult renal transplant recipients. Recipients with the POR*28 allele have lower standardized trough concentrations of TAC.
Article
Multidisciplinary Sciences
Woo-Seok Jung, Jae Hee Kuh, Leerang Lim, Hae Kyung Yoo, Jae-Woo Ju, Ho-Jin Lee, Won Ho Kim
Summary: Despite serious complications, such as infection and recurrence of diseases, corticosteroids are still widely used as immunosuppressive therapy for liver transplant recipients. This study compared the safety and efficacy of T-cell specific antibody induction with corticosteroid induction and found that T-cell specific antibody induction significantly reduced the risk of opportunistic infections and metabolic complications.
SCIENTIFIC REPORTS
(2023)
Article
Pharmacology & Pharmacy
Marith I. Francke, Louise M. Andrews, Hoang Lan Le, Jacqueline van de Wetering, Marian C. Clahsen-van Groningen, Teun van Gelder, Ron H. N. van Schaik, Bronno van der Holt, Brenda C. M. de Winter, Dennis A. Hesselink
Summary: Algorithm-based tacrolimus dosing leads to the achievement of the target tacrolimus C-0 in as many as 58% of patients on day 3 after kidney transplantation.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Pharmacology & Pharmacy
Jeroen J. Koomen, Tim R. Knobbe, Tanja Zijp, Daan Kremer, C. Tji Gan, Erik A. M. Verschuuren, Stephan J. L. J. Bakker, Daan J. Touw, Pieter Colin, TransplantLines Investigators
Summary: This study aimed to establish plasma concentration ranges reflecting the currently used target ranges of whole blood tacrolimus concentrations. By developing a pharmacokinetic model and performing simulations, it was found that the whole blood target ranges for kidney and lung transplant recipients corresponded to plasma concentration ranges of 0.06-0.26 ng/mL and 0.10-0.93 ng/mL, respectively.
CLINICAL PHARMACOKINETICS
(2023)
Review
Medicine, Research & Experimental
Milosz Miedziaszczyk, Ilona Idasiak-Piechocka
Summary: Tacrolimus and omeprazole are commonly used drugs in kidney transplant patients. However, simultaneous administration may lead to drug interactions, affecting the pharmacokinetics of tacrolimus and potentially causing adverse reactions. It is important to address these interactions and find appropriate solutions.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Pharmacology & Pharmacy
Lekshmy Srinivas, Noble Gracious, Radhakrishnan R. Nair
Summary: Tacrolimus is an immunosuppressant used in solid organ transplantation. This study in South Indian renal transplant recipients investigated the effects of gene polymorphisms on tacrolimus concentrations and adverse effects. The findings suggest that genotype-guided initial dosing of tacrolimus can help achieve optimal drug levels and prevent adverse effects.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Junjun Mao, Yuhao Chen, Luyang Xu, Weihuang Chen, Biwen Chen, Zhuo Fang, Weiwei Qin, Mingkang Zhong
Summary: The aim of this study was to identify the important factors affecting cyclosporine (CsA) blood concentration and estimate CsA concentration using seven different machine learning algorithms. The results showed that the predictive performance of nonlinear-based ML models was superior to that of linear regression, and the ML model built with the artificial neural network algorithm was considered the most suitable. Furthermore, the ML models outperformed the previously built population pharmacokinetic model.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Pere Fontova, Helena Colom, Raul Rigo-Bonnin, Oriol Bestard, Anna Vidal-Alabro, Lisanne N. van Merendonk, Gema Cerezo, Carolina Polo, Nuria Montero, Edoardo Melilli, Anna Manonelles, Maria Meneghini, Ana Coloma, Josep M. Cruzado, Joan Torras, Josep M. Grinyo, Nuria Lloberas
Summary: Tacrolimus is considered a key calcineurin inhibitor in transplantation, with the extended-release Meltdose formulation exhibiting superior bioavailability compared to the immediate-release formulation. This study aimed to compare the pharmacodynamic/pharmacokinetic profiles of Tac-IR and Tac-LCP and found that despite higher peak plasma concentrations after Tac-IR, it did not result in stronger inhibition of calcineurin activity compared to Tac-LCP. Tac-LCP demonstrated more sustained inhibition of calcineurin activity between dose intervals, suggesting potential improvement in the pharmacodynamics of Tacrolimus.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Immunology
John A. Mackintosh, Stephanie T. Yerkovich, Maxine E. Tan, Luke Samson, Peter M. A. Hopkins, Daniel C. Chambers
Summary: This study aimed to measure telomere lengths of bronchial and bronchiolar airway cells early after lung transplantation and investigate their associations with CLAD and all-cause mortality. The results showed that airway telomere length was associated with donor age and smoking history, but not with the development of CLAD or all-cause mortality in this cohort.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Kezhen Zong, Dadi Peng, Hang Yang, Zuotian Huang, Yunhai Luo, Yihua Wang, Song Xiang, Tingting Li, Tong Mou, Zhongjun Wu
Summary: This is the first systematic review and meta-analysis to identify factors contributing to poor antibody response in organ transplant recipients after receiving the 2-dose SARS-CoV-2 vaccine. The results suggest that age, diabetes mellitus, low eGFR, MPA or MMF use, high-dose corticosteroids use, and triple immunosuppression therapy are possible independent risk factors for negative antibody response. Additionally, mTOR inhibitor may be a protective factor against weak antibody response.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Katherine W. W. Dewey, Bo Yen, Jose Lazo, Leslie Seijo, Ripal Jariwala, Rupal J. J. Shah, David Quan, Bethanne Carpenter, Jonathan Paul Singer, Karen Breen, Steven Hays, Rebecca Florez
Summary: This study showed that nirmatrelvir/ritonavir can be safely used in lung transplant recipients stabilized on tacrolimus with close monitoring of tacrolimus levels and appropriate dose adjustments. Further research is needed to determine the optimal therapeutic drug monitoring and tacrolimus dose following nirmatrelvir/ritonavir therapy in solid organ transplant recipients.
Review
Medicine, General & Internal
Yangyang Duan, Xueqi Wang, Qiubo Li, Shijiang Sun, Xi Liang, Huijing Li, Jing Huang, Tianhe Zhao, Jingnan Hu, Jianxin Liu, Zhenbiao Hu, Jianming He
Summary: Infliximab, cyclosporine, and tacrolimus are effective salvage therapies for ulcerative colitis. Tacrolimus has the highest efficacy in achieving long-term clinical remission, while cyclosporine is the most cost-effective option compared to infliximab or tacrolimus.
Article
Biotechnology & Applied Microbiology
Leila Amini, Dimitrios Laurin Wagner, Uta Roessler, Ghazaleh Zarrinrad, Livia Felicitas Wagner, Tino Vollmer, Desiree Jacqueline Wendering, Uwe Kornak, Hans-Dieter Volk, Petra Reinke, Michael Schmueck-Henneresse
Summary: In response to the issues of toxicity and inefficacy of antiviral drugs for transplant recipients, researchers have developed a new gene-edited T cell therapy that shows comparable performance with unmodified T cells in vitro, demonstrating tacrolimus resistance and utilizing cyclosporine A as a safety switch. Safety assessments have been conducted as a prerequisite for translation to first-in-human applications.